CD33-Directed Immunotherapy with Third-Generation Chimeric Antigen Receptor T Cells and Gemtuzumab Ozogamicin in Intact and CD33-Edited Acute Myeloid Leukemia and Hematopoietic Stem and Progenitor Cells

By
Justin.choi
-
0
20
Investigators introduced a CD33-directed third-generation CAR T cell product for the treatment of patients with acute myeloid leukemia.
[International Journal of Cancer]
Abstract